N/A N=90 PERIODONTAL DISEASE AND HYPERLIPIDEMIA
Hyperlipidemia, Periodontitis, Gingivitis
Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Short-term Effect of 2% Atorvastatin Dentifrice in Periodontal Status.
Chronic Periodontitis
Primary: Change in Periodontal Inflammation Surface Area (PISA) — 638.16; 288.72 square millimeters
Phase 4 N=49 Compare Anti-inflammatory Dentifrices
Gingivitis
Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05
Phase 3 N=38 Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis
Aggressive Periodontitis
Primary: Change in Probing Depth — 3.88; 3.74; 3.38; 3.26 milimeters — p=<0.05
Phase 3 N=102 Periodontal Infection and Endothelial Dysfunction
Periodontitis
Primary: Brachial Artery Flow-mediated Dilation — 10.2; 10.3; 13.1; 8.1 Percentage of dilatation of brachial art — p=0.98
Phase 3 N=34 Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis
Residual Disease · Aggressive Periodontitis
Primary: Clinical Attachment Level at Baseline, 3 Months and 6 Months — 5.5; 5.29; 4.64; 4.73 mm
N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Phase 4 N=43 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
Osteoporosis, Postmenopausal · Periodontitis
Primary: Sost Values for 6th Month — 1389.177; 1085.405; 1596.585; 2131.87 ng/ml — p=<0.01
Phase 2 N=55 The Effects of DHA on Periodontitis
Periodontitis · Gingivitis · Inflammation
Primary: Change in Pocket Depth (mm) — -0.71; -0.54 mm — p=<0.05
Phase 4 N=113 Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population
Periodontal Disease · Type 2 Diabetes Mellitus
Primary: Glycated Hemoglobin A1c — 8; 8.2 percentage of Glycated Hemoglobin A1c
N/A N=5,117 Periodontal Disease Prevention Study
Periodontitis
Primary: Percentage of Participants With Tooth Loss Over 16 Year Period — 16.4; 13.8; 22.1; 16.9 percentage of participants
N/A N=70 Changes in the Risk Factors of Coronary Heart Disease Observed After Scaling and Root Planing
Coronary Heart Disease · Periodontitis
Primary: Change From Baseline in C-Reactive Protein Level at 6 Months — 6.30; 4.94 mg/L
N/A N=51 Kidney and Periodontal Disease Study
Chronic Kidney Disease · Periodontal Disease
Primary: Number of Participants Completing Study Protocol — 17; 34; 14; 30 Participants
Phase 4 N=50 Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients
Periodontal Diseases
Primary: Change in Clinical Attachment Level (CAL) — 7.0; 6.9 millimeters
N/A N=61 Trial of Toothpaste to Reduce Plaque and Inflammation
Plaque · Inflammation
Primary: Change in Oral Plaque — -1.05; -0.03 log(percentage) — p=0.001
N/A N=18 Role of Infected Blood Dendritic Cells in Heart Disease Risk
Chronic Periodontitis
Primary: Frequency of Blood Dendritic Cells From Baseline — 12; 14 % MFI
N/A N=74 Lipids, Inflammation, and CV Risk in RA
Rheumatoid Arthritis · Cardiovascular Disease
Primary: Coronary Flow Reserve — 2.65 ratio
Phase 3 N=39 Collection of Gingival Crevicular Fluid From Periodontitis Patients
Gingival Diseases
Primary: Metabolite Associated With Inflammation (Cadaverine) — 1.119186; 0.92077 ion count — p=<0.05
Phase 2 N=114 Impact of Periodontal Therapy on Patients With Diabetes
Diabetes Mellitus, Type II · Periodontitis
Primary: Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline — -0.25; -0.18 mm — p=0.16
Phase 2 N=127 Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis
Gingival Inflammation
Primary: Incidence of Adverse Events — 19; 10; 3 Participants
Phase 2 N=46 Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis
Peri-implant Mucositis
Primary: Change in Interleukin 1 B at Base to 24 Hours — -1.075; 1.013 Micrograms per deciliter (ug/dl) — p=0.90
N/A N=34 Effect of Non-surgical Periodontal Therapy on Gingival Crevicular Fluid Interleukin-21 Levels
Chronic Peridontitis Patients · Chronic Gingivitis · Healthy
Primary: Pocket Depth — 1.60; 2.50; 6.75 millimetres
N/A N=60 Activated MMP-8 as Diagnostic Test for Periodontitis
Generalized Chronic Periodontitis
Primary: Percentage of True Positive/Negative aMMP-8 Tests of All Periodontitis Patients (Sensitivity/Specificity) — 87; 60 percentage of true cases (sens./spec.)
N/A N=69 IFI16 is a Periodontitis Modulating Protein
Severe Periodontitis · Acute Inflammatory Response
Primary: Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels — 0.37; 0.65 fold change — p=0.3
Phase 4 N=51 Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis
Periodontitis
Primary: Periodontal Probing Depth — 2.5; 3.2; 3.4 millimeter
N/A N=32 Induced Gingivitis & Intra-oral Imaging
Plaque Induced Gingivitis
Primary: Change From Baseline Gingivitis at Day 14 as Measured by Non-invasive Microimaging and Gingival Index. — 0.6; 0.15 units on a scale
Phase 3 N=60 Effectiveness of a Triclosan Containing Toothpaste in Maintaining Periodontal Health in a Type 2 Diabetic Population
Periodontitis
Primary: HbA1c Levels in Blood — 11.42; 10.81 percentage of HbA1c levels in blood — p=0.05
Phase 2 N=146 Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers
Periodontitis · Periodontal Diseases
Primary: Change in Mean Clinical Attachment Level. — 0.11; 0.10; 0.21; 0.08 mm — p=>0.05
N/A N=38 Local and Systemic Antimicrobials in Non-surgical Periodontal Therapy
Periodontitis
Primary: Change in Pocket Probing Depth (PPD) — 3.932; 4.082; 3.253; 3.294 mm
Early Phase 1 N=35 Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model
Gingivitis
Primary: Proportion of Sites That Bleed on Probing